- Soliton
is positioning its proprietary technology as a new standard of care in the
multimillion-dollar tattoo-removal industry
- The
company recently filed a 501(k) with the FDA for its Rapid Acoustic Pulse
tattoo-removal device
- Soliton’s
cellulite reduction clinical trials have been featured on Yahoo
Finance’s First Trade live stream
Medical device company Soliton Inc. (NASDAQ: SOLY) plans to
launch its Rapid Acoustic Pulse (RAP) device into the tattoo-removal market,
positioning it as the new standard of care. The company also plans to complete
its fat and cellulite reduction trials by 2023. The valuable new RAP technology
is licensed from the University of Texas on behalf of the MD Anderson Cancer
Center. The RAP device is covered by eight patent families representing 38
issued or pending patents worldwide.
Tattoo removal is on the rise, and the surrounding industry
is forecast to reach $4.8 billion by 2023. Laser therapy holds 66 percent of
the market but is time consuming and costly (http://ibn.fm/8n9rm). Typical laser treatment for tattoo
removal results in an 11-16 percent reduction in pigment and requires 10 to 20
visits over a two-year period for the complete removal of the tattoo because of
the body’s reaction to the treatment and the need for healing between
appointments.
The conventional method is painful, damages the skin and
lacks predictable results; the method also costs up to $3,500 or more. When
using the RAP device, multiple laser passes can be performed in a
single-treatment session. This reduces visits down to two or three for tattoo
removal, which also reduces the cost.
In a recent clinical study, 100 percent of the tattoos
treated with Soliton RAP achieved 75 percent fading in three or fewer office
visits, supporting the company’s claim of being three or more times faster than
conventional methods. The RAP device uses very high energy — around 3,000 volts
at nearly 3,000 amps — to form acoustic shockwaves 100 times per second. The
acoustic waves are virtually painless, do not damage the skin and are
divergent, thus eliminating heat. Soliton recently filed for a 501(k) with the
FDA for its RAP tattoo-removal device (http://ibn.fm/RKmEt), which is not currently available for
sale.
Soliton has a strong commitment to science and is conducting
animal and human trials to confirm the safety and efficacy of the technology.
The company believes in transparency, and the results of its clinical trials
can be found on its website at www.Soliton.com. The technology is currently undergoing fat
clinical trials and a cellulite reduction trial.
Soliton recently announced that its manufacturing partner
has delivered the first replaceable cartridge targeting cellulite
reduction (http://ibn.fm/CSr81).
This cartridge delivers the high-powered acoustic pulses at even greater depths
than the tattoo-removal cartridge.
“We are very enthusiastic about the flexibility that our
interchangeable treatment heads will bring to the practitioners that partner
with us for the treatment of cellulite reduction and tattoo removal,” Dr. Chris
Capelli, Soliton president, CEO and co-founder, stated in a news release. “Our
therapy will be delivered through single-use cartridges that are designed to be
used for one patient treatment. Once our device is cleared by the FDA, we
expect to deliver a recurring revenue stream and drive top-line growth for the
company.”
On May 13, 2019, Soliton was featured on First Trade,
the new live-streaming Yahoo Finance show (http://ibn.fm/WP4sg). The focus during the segment was on
the newly released cellulite clinical trial data. Soliton is strategically
positioned to serve a global market combating cellulite, which is estimated to
reach $1.4 billion by 2026.
For more information, visit the company’s website at www.Soliton.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php

No comments:
Post a Comment